New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2013
09:11 EDTNUVANuVasive says received FDA warning letter related to San Diego facility
On March 13, NuVasive received a warning letter dated March 12 from the FDA related to an inspection of the company’s San Diego, California facility that occurred from October 29, 2012 through November 2, 2012. The inspection did not result in any 483 observations and the warning letter does not cite any quality system concerns.The FDA letter identifies specific labeling claims related to the company’s ILIF procedure, indicating that one of the indications noted is not cleared through any of the company’s Affix Spinous Process Plate system 510(k)s. The letter only relates to this promotional claim and the company does not anticipate a disruption in the distribution of these products. The company takes this matter seriously and has already begun to respond to the FDA’s requests. The company is giving the matter the highest priority in order to fully address the FDA’s concerns to our mutual satisfaction. As this is an administrative process to address the warning letter, the company believes the FDA’s concerns can be resolved without an impact on the company’s financial results or operations. Comments taken from an 8-K filing.
News For NUVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 26, 2015
12:03 EDTNUVANuVasive CEO news an incremental positive, says Piper Jaffray
Piper Jaffray views NuVasive's naming Greg Lucier as its permanent CEO as an incremental positive despite the executive's lack direct experience in the spine industry. Piper notes its channel checks indicate no meaningful sales force disruption from the CEO transition. It reiterates an Overweight rating on NuVasive with a $56 price target.
10:13 EDTNUVAHigh option volume stocks
08:36 EDTNUVANuVasive appoints Gregory Lucier as CEO
Subscribe for More Information
May 14, 2015
13:58 EDTNUVANuVasive initiated with a Market Perform at Northland
Target $46.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use